Armand Desanctis, MD
Internal Medicine · Wilmington, DENPI 1558463299
Payments from drug & device makers
Across 609 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Astellas Pharma US Inc$1K
- Lilly USA, LLC$828
- Esperion Therapeutics, Inc.$612
- Johnson & Johnson$584
- plus $4K from 25 others
What the payments were for
- Food & beverage$10,45696%
- Education$4384%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 61 | $2,141 |
| GSK | 91 | $1,295 |
| Astellas Pharma US Inc | 66 | $1,190 |
| Lilly USA, LLC | 51 | $828 |
| Esperion Therapeutics, Inc. | 41 | $612 |
| Johnson & Johnson | 32 | $584 |
| Pfizer | 35 | $568 |
| AbbVie(2 entities) | 34 | $500 |
| Boehringer Ingelheim | 33 | $486 |
| Merck | 30 | $477 |
| Novartis | 32 | $401 |
| Kowa Pharmaceuticals America, Inc. | 28 | $376 |
| Novo Nordisk | 19 | $356 |
| Amarin Pharma, Inc. | 11 | $282 |
| Amgen(2 entities) | 12 | $193 |
| Sanofi Pasteur Inc. | 5 | $113 |
| Genentech USA, Inc. | 4 | $79 |
| Biohaven Pharmaceuticals, Inc. | 4 | $67 |
| Idorsia Pharmaceuticals US Inc | 3 | $62 |
| Eisai Inc. | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $37 |
| Tactile Systems Technology Inc | 1 | $27 |
| Abbott | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,895 in reported general payments places this provider in the 95th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 311 | $419,488 |
| TrulicityDulaglutide | 119 | $159,834 |
| JanuviaSitagliptin Phosphate | 99 | $130,039 |
| EliquisApixaban | 105 | $119,623 |
| FarxigaDapagliflozin Propanediol | 55 | $81,628 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $56,765 |
| JardianceEmpagliflozin | 34 | $42,648 |
| OzempicSemaglutide | 26 | $24,224 |
| XareltoRivaroxaban | 23 | $19,875 |
| RybelsusSemaglutide | 12 | $17,496 |
| Olmesartan Medoxomil | 559 | $15,213 |
| Rosuvastatin Calcium | 772 | $15,130 |
| Atorvastatin Calcium | 785 | $12,071 |
| OxycontinOxycodone Hcl | 22 | $11,165 |
| MyrbetriqMirabegron | 12 | $8,818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $828 | $579,323430 claims |
| MerckJanuvia | $477 | $130,03999 claims |
| PfizerEliquis | $568 | $119,623105 claims |
| AstraZenecaFarxiga | $2,141 | $81,62855 claims |
| GSKTrelegy Ellipta | $1,295 | $56,76547 claims |
| Boehringer IngelheimJardiance | $486 | $42,64834 claims |
| Novo NordiskOzempic, Rybelsus | $356 | $41,72038 claims |
| Johnson & JohnsonXarelto | $584 | $19,87523 claims |
| Astellas Pharma US IncMyrbetriq | $1,190 | $8,81812 claims |
| AbbVieSynthroid | $500 | $3,31377 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 477 internal medicine providers in Delaware.
Other internal medicine in Wilmington
- Jose CastroWilmington$27K
- Marcia Gina CastroWilmington$24K
- Robert KopeckiWilmington$15K
- Franklin AmpaduWilmington$15K
- Andrew MyersWilmington$15K
- Carol Alvarado-BarrantesWilmington$10K
- Stuart FelzerWilmington$6K
- Terry HortonWilmington$5K
- Jerry GluckmanWilmington$5K
- Alina GoverWilmington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.